![](/img/cover-not-exists.png)
The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors
Karimian, Zahra, Mavoungou, Sandra, Salem, Joe-Elie, Tubach, Florence, Dechartres, AgnèsVolume:
20
Journal:
BMC Cancer
DOI:
10.1186/s12885-020-07518-5
Date:
December, 2020
File:
PDF, 1.51 MB
2020